Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tarsons Products's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹-58 Mil. Tarsons Products's average total tangible assets for the quarter that ended in Jun. 2026 was ₹11,261 Mil. Therefore, Tarsons Products's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -0.51%.
The historical rank and industry rank for Tarsons Products's Return-on-Tangible-Asset or its related term are showing as below:
BOM:543399'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.03 Med: 15.16 Max: 25.32
Current: 1.03
During the past 8 years, Tarsons Products's highest Return-on-Tangible-Asset was 25.32%. The lowest was 1.03%. And the median was 15.16%.
BOM:543399's Return-on-Tangible-Asset is ranked better than 50.7% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.92
vs BOM:543399: 1.03
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Tarsons Products Return-on-Tangible-Asset Related Terms
Tarsons Products Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Tarsons Products's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543399 vs ISRG, BDX, RMD: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Tarsons Products's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsons Products Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tarsons Products's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Tarsons Products's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -0.51% mean?
Tarsons Products (BOM:543399) has a Return-on-Tangible-Asset of -0.51% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tarsons Products and its competitors. Over the past decade, Tarsons Products' Return-on-Tangible-Asset has ranged from 1.03 to 25.32. According to the industry distribution chart, Tarsons Products ranks #420 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 49.3%.
Is Tarsons Products' Return-on-Tangible-Asset too high?
Tarsons Products' current Return-on-Tangible-Asset is -0.51%. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 25.32. Based on the distribution chart, Tarsons Products ranks #420 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tarsons Products has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tarsons Products ranks #420 out of 852 companies for Return-on-Tangible-Asset. This puts Tarsons Products in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.92. Historically, Tarsons Products' own Return-on-Tangible-Asset has ranged from 1.03 to 25.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.92, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tarsons Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsons Products's current Return-on-Tangible-Asset is -0.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (BOM:543399) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹468.88, compared to a current price of ₹331.05 — trading 29.4% below its estimated fair value. The current Return-on-Tangible-Asset is -0.51%. Tarsons Products' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Tarsons Products (BOM:543399), the current Return-on-Tangible-Asset is -0.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsons Products (BOM:543399) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued.
The current stock price of ₹331.05 is trading 29.4% below its estimated GF Value™ of ₹468.88.
GuruFocus considers Tarsons Products to be Modestly Undervalued.
Key valuation signals for BOM:543399:
Return-on-Tangible-Asset: -0.51%
GF Value™: ₹468.88 vs. price of ₹331.05 (29.4% below fair value)
No single metric tells the full story. See the BOM:543399 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
84GF Score
Get the complete analysis for BOM:543399
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543399 has been successfully added to your 
